Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

February 4-6, 2016
San Diego, CA

Scientific Agenda

Thursday, February 4, 2016

8:00 am

Opening remarks and pre-survey
Lee M. Ellis, MD

Session I: Basic Science: Update on Angiogenesis

Moderator: Lee M. Ellis, MD

8:20 am

Basic and translational science of angiogenesis
Robert S. Kerbel, PhD

8:45 am

ANG2/TIE2, macrophages, angiogenesis, and immunity
Michele De Palma, PhD

9:10 am

Abstract presentation 1
Selected abstract presenter  

9:25 am

Role of fibroblasts in mechanisms of tumor angiogenesis
Napoleone Ferrara, MD

9:50 am

Tie-2 and Notch Signaling and Inhibition
Adrian L. Harris, MD, DPhil

10:15 am


Session II: Basic Science: Update on Tumor Microenvironment

Moderator: Robert Kerbel, PhD

10:30 am

Stromal targeting
Speaker invited

10:55 am

Abstract presentation 2
Selected abstract presenter

11:10 am

Inflammation in cancer
Michael Karin, PhD

11:35 am

Characterization of the immune microenvironment
Thomas F. Gajewski, MD, PhD

12:00 pm


Session III: Crosstalk in the Tumor Microenvironment and Preclinical Modeling

Moderators: Mario Sznol, MD

1:15 pm

Macrophage crosstalk
Dmitry I. Gabrilovich, MD, PhD

1:40 pm

Abstract presentation 3
Selected abstract presenter

1:55 pm

Anti-CD47 therapy
Ravindra Majeti, MD, PhD

2:20 pm

Preclinical modeling
Karolina Palucka, MD, PhD

2:45 pm

Signal transduction targeted therapies as immunotherapy
Keith Flaherty, MD

Day 1 Closing

3:10 pm

Closing remarks and post-survey
Lee M. Ellis, MD

3:30 pm


3:45 pm

Poster viewing and reception

5:00 pm


Friday, February 5, 2016

8:00 am

Opening remarks and pre-survey
Helen X. Chen, MD

Session IV: Novel Approaches to Activate the Immune Response to Tumor Antigens

Moderator:  Helen X. Chen, MD

8:20 am

Whole-exome sequencing and neoantigen in vaccine strategy
Gerald P. Linette, MD, PhD

8:45 am

Combining immune checkpoint inhibitors
Mario Sznol, MD

9:10 am

Novel approaches to block immune suppression: adenosine 2aR inhibitors, checkpoints, and IDO
Hassane Zarour, MD

9:35 am

T cell therapy  
Speaker invited

10:00 am

CAR T-cell therapy
Laurence Cooper, MD, PhD

10:25 am


Session V:Interactions Between Angiogenesis and Immune Response

Moderator:  George W. Sledge, Jr, MD

10:40 am

Targeting hypoxia-inducible factor for cancer therapy: Why is it taking so long?
Adrian L. Harris, MD, DPhil*

11:05 am

Abstract presentation 4
Selected abstract presenter

11:20 am

Crosstalk between angiogenesis antiangiogenesis/anti-VEGF and immunotherapy
David P. Carbone, MD, PhD

11:45 am


Session VI: Biomarkers and Predictors of Response

Moderator:  Axel Grothey, MD

1:00 pm

Biomarkers for immune therapy
Lisa H. Butterfield, PhD

1:25 pm

Biomarkers for anti-angiogenic therapy
David Stewart, MD

2:15 pm

Abstract presentation 5
Selected abstract presenter

2:30 pm

Gordon C. Jayson, MD, PhD*

2:55 pm


Session VII: Targeting Angiogenesis and the Tumor Microenvironment: Clinical Trial Overview

3:15 pm

Bladder cancer
Dan Theodorescu, MD, PhD

3:40 pm

Renal cell carcinoma
Eric Jonasch, MD

4:05 pm

Lung cancer
Ramaswamy Govindan, MD

Day 2 Closing

4:55 pm

Closing remarks and post-survey
Axel Grothey, MD

5:15 pm


Saturday, February 6, 2016

8:00 am

Opening remarks and pre-survey
Mario Sznol, MD

Session VII: Targeting Angiogenesis and the Tumor Microenvironment: Clinical Trial Overview (continued)

Moderators:  George W. Sledge, Jr, MD and Mario Sznol, MD

8:20 am

Breast cancer
George W. Sledge, Jr, MD

8:45 am

Gliobalstoma multiforme
David Reardon, MD

9:10 am

Michael B. Atkins, MD

9:35 am

Colorectal cancer
Axel Grothey, MD

10:00 am

Hepatocellular cancer
Anthony El-Khoueiry, MD

Day 3 Closing

10:25 am

Closing remarks and post-survey
George W. Sledge, Jr, MD

10:45 am